[ad_1]
PARIS, April 26, 2022 (GLOBE NEWSWIRE) — Tribun Health (Formerly Tribvn Healthcare) is pleased to announce the company’s expansion into the pharmaceutical market with the appointment of Mr. Loic Dartois as Vice President Pharma. After graduating from ESIEE Management Paris in Biotechnologies, Loic started his career at Sanofi as a product manager, where he was able to demonstrate his skills in business development and knowledge of the medical field. Loic quickly became Business Development Director with Several companies such as Optum, Quintiles, ICON and more recently PPD. Having just recently graduated from ESSEC, where he obtained his MBA with honors, Loic has more than 15 years of experience in the pharmaceutical, clinical development and real-world evidence industries. Tribun Health looks forward to leveraging Loic’s experience and success to develop the important and expanding pharmaceutical market.
Tribun Health has a successful track record of providing solutions to the preclinical pharmaceutical and biotech market. In 2021, the company was a finalist in the iTech Awards organized by Sanofi. This was a great opportunity to work with Sanofi’s team and develop an AI solution using histology data to predict the response of patients to targeted therapies. This project has been particularly relevant to demonstrate that histology data can improve clinical trial endpoints and be used to develop companion diagnostics.
With the rapid adoption of digital pathology coupled with the integration of AI into clinical practicereal-world data in histology is becoming far more accessible for drug discovery: “The progress in computational pathology allows a complete mapping and phenotyping of the tumor. AI has the power to extract relevant information from large amounts of real-world data and turn it into actionable insights that predict disease evolution and response to targeted therapies. This will contribute to new drug development, accelerating drug discovery, reducing risk on clinical trials’ endpoints, and fostering the rise of companion diagnosis,” says
Full story available on Benzinga.com [ad_2]
Source link
